ACADIA Pharmaceuticals（ACAD）株式概要
バイオ医薬品会社であるアカディア・ファーマシューティカルズ・インクは、北米における神経疾患および希少疾患治療薬の開発と商業化に注力している。 詳細
ACAD Community Fair Values
Create NarrativeSee what 104 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$28.75
FV
26.6% 割安 内在価値ディスカウント10.02%
Revenue growth p.a.
28
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ACADIA Pharmaceuticals Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$21.10 |
| 52週高値 | US$28.35 |
| 52週安値 | US$19.69 |
| ベータ | 0.86 |
| 1ヶ月の変化 | -3.92% |
| 3ヶ月変化 | -14.19% |
| 1年変化 | -4.00% |
| 3年間の変化 | -14.85% |
| 5年間の変化 | -5.55% |
| IPOからの変化 | 214.93% |
最新ニュース
Recent updates
ナラティブの更新 • May 09
ACAD: Remlifanserin Alzheimer’s Psychosis Readout Will Drive Upside From Undervalued Levels
Analysts recently adjusted their fair value estimate for ACADIA Pharmaceuticals slightly lower to $43.55 from $43.97, reflecting updated assumptions for revenue growth, profitability, and future P/E. This revision also incorporates mixed but generally constructive Street price target updates in the $26 to $37 range, along with several fresh Buy and Outperform ratings.
ナラティブの更新 • Apr 23
ACAD: Execution Risk Around Rett Syndrome Setback Will Limit Future Upside
Analysts trimmed the fair value estimate for ACADIA Pharmaceuticals slightly to $19.64 from $19.73, as modestly higher discount rate assumptions offset slightly stronger projected revenue growth and profitability. They maintained a supportive stance following a mix of recent price target increases and reductions across the Street.
ナラティブの更新 • Apr 08
ACAD: Future Upside Will Depend On Alzheimer Psychosis Trial Outcomes
The fair value estimate for ACADIA Pharmaceuticals has increased slightly to $31.80, as analysts incorporate updated revenue growth assumptions, mixed adjustments to price targets across firms, and ongoing expectations for contributions from Nuplazid, Daybue, and the broader pipeline. Analyst Commentary Recent research coverage on ACADIA Pharmaceuticals shows a mix of optimism and caution, with several firms revising price targets after earnings updates, guidance, and pipeline commentary.ナラティブの更新 • Mar 24
ACAD: Remlifanserin Alzheimer’s Psychosis Data Will Drive Upside From Undervalued Levels
ACADIA Pharmaceuticals' updated analyst price target moves from $37 to about $44, with analysts pointing to refreshed models that reflect recent guidance, ongoing commercial momentum in Nuplazid and Daybue, and growing attention on the remlifanserin Phase 2 program in Alzheimer's disease psychosis. Analyst Commentary Recent Street research around ACADIA Pharmaceuticals clusters around refreshed models, updated sales assumptions for Nuplazid and Daybue, and rising interest in the remlifanserin program in Alzheimer's disease psychosis.ナラティブの更新 • Mar 10
ACAD: Trofinetide EU Setback And Execution Risks Will Likely Restrain Upside
ACADIA Pharmaceuticals' updated analyst price target reflects a modest reset in fair value to $19.73 from $20.26, as analysts balance recent target revisions across the Street with refreshed assumptions for growth, margins, and future P/E levels. Analyst Commentary Across recent research updates, views on ACADIA are mixed, with several large firms expressing confidence in the commercial trajectory of Nuplazid and Daybue, while others are more measured and focused on execution risks and how much of the current pipeline is already reflected in the share price.ナラティブの更新 • Feb 23
ACAD: Pipeline And Execution Risks Will Likely Cap Upside Despite Renewed Optimism
ACADIA Pharmaceuticals' updated fair value estimate has edged up from $19.65 to $20.26 per share, reflecting analysts' higher price targets tied to confidence in Nuplazid and Daybue, as well as underappreciated upside from the remlifanserin pipeline asset. Analyst Commentary Recent research views on ACADIA are mixed, with some firms pointing to upside tied to Nuplazid, Daybue, and the remlifanserin program, while others are more guarded.ナラティブの更新 • Feb 09
ACAD: Higher P/E Assumptions Will Rely On Successful Rett Syndrome Expansion
Analysts have nudged their fair value estimate for ACADIA Pharmaceuticals higher by about $0.47 per share, reflecting recent price target revisions and updated assumptions around revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent Street research on ACADIA Pharmaceuticals has been active, with multiple firms revising price targets and updating their views on the company.ナラティブの更新 • Jan 25
ACAD: Execution Risk And Sector Capital Pressures Will Likely Constrain Upside
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing updated assumptions around revenue growth, profitability and future P/E expectations, alongside a generally cautious but constructive view on Biotech, with potential M&A activity helping to support the sector. Analyst Commentary While the updated US$40 target signals constructive sentiment on ACADIA Pharmaceuticals, recent commentary still carries a cautious tone around how the story plays out over time.ナラティブの更新 • Jan 11
ACAD: Higher P/E Assumptions Will Support Upside If Pipeline Milestones Deliver
Narrative Update Analysts have lifted their price target on ACADIA Pharmaceuticals to US$40 from US$35, citing a refreshed view on fair value, updated discount rate assumptions, and adjusted expectations for revenue growth, profit margin, and future P/E multiples. Analyst Commentary Recent commentary around ACADIA Pharmaceuticals reflects a mix of optimism on potential value creation and caution around sector level capital trends.ナラティブの更新 • Dec 26
ACAD: Expanded Neuroscience Pipeline Will Drive Upside From Undervalued Levels
Analysts have modestly increased their price target on ACADIA Pharmaceuticals from 35.00 dollars to 37.00 dollars. They cited slightly stronger long term revenue growth, improved profit margin expectations, a marginally lower discount rate, and a higher projected future price to earnings multiple.ナラティブの更新 • Dec 12
ACAD: Upcoming Neuropsychiatric Data Expected To Drive Upside Despite Recent Setback
Analysts have trimmed their price target on ACADIA Pharmaceuticals by $5 to $35 per share. This reflects a modestly higher discount rate and lower long term profit expectations, despite slightly stronger projected revenue growth and reassurance that the ACP-101 failure has only a small impact on overall valuation.Seeking Alpha • Dec 04
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
Summary Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID’s patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest. ACP-204’s mid-2026 Phase 2 data in Alzheimer’s psychosis is a major catalyst; ACAD's financials remain robust and profitable. Read the full article on Seeking Alpha分析記事 • Nov 13
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings recently, the stock hasn't reacted in a...分析記事 • Nov 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) came out with its quarterly results last week, and we wanted to see how the...ナラティブの更新 • Sep 26
Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA Pharmaceuticals’ consensus price target was revised downward to $29.32 as the Phase 3 failure of ACP-101 in Prader-Willi syndrome modestly reduced pipeline value, though the impact is seen as limited given low expectations and resilience in the core business. Analyst Commentary Bearish analysts cite the Phase 3 failure of ACP-101 in Prader-Willi syndrome (PWS), which missed its primary endpoint, leading to lowered price targets based on reduced near-term pipeline value.ナラティブの更新 • Sep 04
Global Outreach And Pipeline Programs Will Expand CNS Markets
Analysts maintained their price target for ACADIA Pharmaceuticals at $29.95 as strong Daybue growth, favorable Nuplazid patent rulings, and strategic R&D focus offset near-term competitive and pipeline uncertainties. Analyst Commentary Bullish analysts are raising price targets citing strong Daybue growth in Q2, but note further acceleration is needed for material upside.分析記事 • Aug 09
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community and...分析記事 • May 30
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Surges 54% Yet Its Low P/S Is No Reason For Excitement
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shares have had a really impressive month, gaining 54% after a shaky period...分析記事 • May 09
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) just released its first-quarter report and things are looking bullish...分析記事 • Mar 03
ACADIA Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) last week reported its latest annual results, which makes it a good time...Seeking Alpha • Feb 13
Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Summary Acadia Pharmaceuticals has shown significant financial improvement, reporting a profit of $82.7m in 2024, compared to a loss of $(107m) in 2023. The company's revenue growth is driven by NUPLAZID and DAYBUE, with 2024 revenue projections of $600m-$610m and $340m-$350m respectively, and overall revenues forecast to exceed $1bn in '25. Acadia's promising pipeline, including ACP-204 and ACP-101, and successful marketing campaigns suggest strong future growth potential. Given the company's profitability, robust pipeline, and undervaluation compared to peers, I am upgrading Acadia from "Sell" to "Buy". Read the full article on Seeking Alpha分析記事 • Jan 08
Why Investors Shouldn't Be Surprised By ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 3.1x ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is...Seeking Alpha • Nov 27
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
Summary NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growth could come from two late-stage assets known as ACP-101 for hyperphagia of PWS and ACP-204 for Alzheimer's Disease Psychosis. Company entered into a worldwide license agreement with Saniona to develop and commercialize SAN711 for the treatment of patients with Essential Tremor; Phase 2 study to be initiated in 2026. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Summary Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also posted updated FY2024 guidance. Acadia Pharmaceuticals is becoming profitable, has a pristine balance sheet, and is seeing solid growth. An updated analysis around ACAD stock follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Nov 08
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with its shares surging 18...
新しいナラティブ • Sep 09
Targeted Campaigns And Pipeline Expansions Set To Revolutionize Growth In Neurological Treatment Market
Targeted and DTC campaigns for NUPLAZID aimed at Parkinson's disease psychosis are expected to notably increase patient starts, directly enhancing market share and revenue.Seeking Alpha • Aug 26
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Summary Shares of Acadia trended lower this year due to Daybue's poor quarterly sales performance, and also due to Nuplazid's failure in the phase 3 trial in schizophrenia patients. The full-year guidance on Daybue was reduced as Acadia is finding fewer new patients, not because of higher patient churn. With most of the headwinds in the rearview mirror, I expect better performance of Daybue going forward. Nuplazid's strong performance remained largely unnoticed given the investor focus on Daybue. Other key pipeline projects are on track with ACP-204, and ACP-101 progressing in phase 2/3 and phase 3 trials, respectively. Read the full article on Seeking Alpha分析記事 • Aug 14
The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Even though ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) posted strong earnings, investors appeared to be underwhelmed...分析記事 • Aug 09
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) investors will be delighted, with the company turning in some strong...分析記事 • Aug 01
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) price-to-sales (or "P/S") ratio of 3.9x might make it look like a strong...分析記事 • May 23
Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
Key Insights ACADIA Pharmaceuticals to hold its Annual General Meeting on 29th of May CEO Steve Davis' total...分析記事 • Apr 24
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
ACADIA Pharmaceuticals Inc.'s ( NASDAQ:ACAD ) price-to-sales (or "P/S") ratio of 3.8x might make it look like a strong...株主還元
| ACAD | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 2.0% | 3.1% | 1.2% |
| 1Y | -4.0% | 34.6% | 28.7% |
業界別リターン: ACAD過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: ACADは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。
価格変動
| ACAD volatility | |
|---|---|
| ACAD Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: ACAD 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ACADの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1993 | 797 | Catherine Owen Adams | www.acadia.com |
アカディア・ファーマシューティカルズ・インク（ACADIA Pharmaceuticals Inc.）は、北米において神経疾患および希少疾患治療薬の開発・商業化に注力しているバイオ医薬品企業。同社は、パーキンソン病精神病に伴う幻覚や妄想を治療する選択的セロトニンインバースアゴニスト／アンタゴニストであるNUPLAZID（ピマバンセリン）、神経炎症を抑えシナプス機能をサポートすることによりレット症候群の症状を治療するインスリン様成長因子1のアミノ末端トリペプチドの新規合成アナログであるDAYBUEを提供しています。また、アルツハイマー型認知症精神病とリーワイ小体型認知症精神病の治療薬として臨床第2相試験中のremlifanserin、大うつ病性障害の治療薬として臨床第2相試験中のACP-211、本態性振戦の治療薬として臨床第1相試験中のACP-711、遅発性ジスキネジアとハンチントン病の治療薬として臨床第1相試験中のGPR88作動薬ACP-271を開発している。また、レット症候群と脆弱X症候群の治療薬として第1相臨床試験中のcGPアナログであるACP-2591、SYNGAP1症候群の探索プログラム中のSTOKEアンチセンス・オリゴヌクレオチド・プログラムも開発している。また、Neuren Pharmaceuticals Limitedとはレット症候群およびその他の適応症を対象としたトロフィネチドに関するライセンス契約を、Stoke Therapeutics, Inc.とは中枢神経系の重篤かつ稀な遺伝性神経発達疾患の治療薬となりうる新規RNAベース医薬品の発見、開発、商業化を目的としたライセンス契約および提携契約を締結している。前身はレセプター・テクノロジーズ・インクで、1997年にアカディア・ファーマシューティカルズ・インクに社名変更。アカディア・ファーマシューティカルズ・インクは1993年に設立され、カリフォルニア州サンディエゴに本社を置いている。
ACADIA Pharmaceuticals Inc. 基礎のまとめ
| ACAD 基礎統計学 | |
|---|---|
| 時価総額 | US$3.61b |
| 収益（TTM） | US$375.65m |
| 売上高(TTM) | US$1.10b |
9.6x
PER（株価収益率3.3x
P/SレシオACAD は割高か？
公正価値と評価分析を参照収益と収入
| ACAD 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.10b |
| 売上原価 | US$420.80m |
| 売上総利益 | US$674.45m |
| その他の費用 | US$298.80m |
| 収益 | US$375.65m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 2.19 |
| グロス・マージン | 61.58% |
| 純利益率 | 34.30% |
| 有利子負債／自己資本比率 | 0% |
ACAD の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 04:27 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ACADIA Pharmaceuticals Inc. 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37
| アナリスト | 機関 |
|---|---|
| Joel Beatty | Baird |
| null null | Baird |
| Jack Allen | Baird |